濮阳东方看妇科收费非常低濮阳东方妇科医院技术很权威,濮阳东方医院看阳痿评价很高,濮阳东方医院妇科非常便宜,濮阳东方妇科口碑好吗,濮阳市东方医院价格不高,濮阳东方医院割包皮非常便宜,濮阳东方妇科公交站

When it's one hundred degrees in Washington D.C., it's hard to get outside to do anything. But for supporters of the late Congressman John Lewis, the opportunity to pay respects to the civil rights icon is worth the sweat. "We knew before coming out here that the heat index would be 105," Lenora Simpson said. "He never stopped, he never gave up, he was always fighting," Simpson added. "I always tell my grandchildren if it wasn’t for the pioneers we don’t know where we would be," Simpson added. Simpson, like so many men and women lining up outside the U.S. Capitol, never met Lewis. They just know his legacy as a fighter for equality. 27 year-old Joshua Maxey, however, did meet Lewis five years ago during an interview. He stood in line Monday thinking of the advice Lewis gave the man. "[He said] now it’s your time, It’s your generations time to pick up the mantle, obviously those words are still stuck with me today," Maxey said. 949

Wildfires continue to ravage the western United States, particularly in the Pacific Northwest, where 28 people have died and officials are bracing for more death.Hundreds of thousands of acres are currently burning in about 100 fires in 13 western states, but areas of Northern California and Oregon have seen unprecedented and catastrophic damage this week.Since mid-Auhust least 19 people have died in California — nine alone in the North Complex Fire that's currently burning north of Sacramento. Eight people have now been killed in Oregon, and with dozens of people still missing, officials are expecting more casualties."We know we're dealing with fire-related death, and we're preparing for a mass fatality incident, based on what we know," said Andrew Phelps, the director of the Oregon Office of Emergency Management.A one-year-old boy was also killed in Washington state this week.USA Today reports that cooler weather this weekend may aid firefighters. But in Oregon, officials fear that two large fires could merge and begin threatening an area near Portland — the state's largest city. More than 500,000 people have already been evacuated, a number representing about 10% of the state's population. 1219

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

While many think of NASA as the government agency that sends scientists into space, some of NASA’s most important work frequently is used to help people on Earth.In recent months, NASA has used its extensive network of scientists and researchers to combat the coronavirus. And in short order, the agency provided patients and healthcare providers with tools that may have been used to save lives.This week, NASA outlined a number of innovations the agency developed to support the fight against the virus.NASA created an open source for N95 respirators so people can make their own masks by using 3D printers. N95 respirators are unique as they protect the wearer from the virus. NASA’s designs were engineered to meet or exceed standard N95 performance, can be used for different purposes, are compatible with commercially-available filters, and do not disrupt the supply chain.If you have access to a 3D printer, here is how to create an N95 respirator designed by NASA.In addition to NASA’s open-source N95 respirators, the team from Johnson Space Center developed and tested a sterilization protocol to combat a national shortage of N95 masks. This allows N95 respirators to be reused by healthcare providers.“I had a very deep and personal connection to the evaluation (of N95 masks), because my wife is a medical professional… on the frontlines, with only one mask allocated for her to use and re-use daily,” said NASA engineer and project lead Jeremy Jacobs. “She has been very concerned about cross contamination between patient-to-patient and to our family.”Among other innovations, NASA’s Jet Propulsion Laboratory in California designed a new high-pressure ventilator tailored specifically to treat COVID-19 patients. It was designed to treat patients who might not require a full-featured ventilator, keeping the nation’s limited supply of traditional ventilators available, NASA said.NASA’s Armstrong Flight Research Center in California joined several other agencies to create a helmet that functions like a continuous positive airway pressure, commonly known as CPAP, machine to force oxygen into a patient’s low-functioning lungs. 2156

Will the iPhone X change your life for the better and usher you into the future, face first? Or is it just another smartphone with a giant screen and a strange little rectangle on top?We've only had the phone since Monday morning. It's more than the few minutes of hands-on time reporters had when the device was launched, but a day is not enough time to fairly review the iPhone X. It's like deciding if you want to marry someone after one blind date.So while we test, tinker and tap this week, here are some first impressions to whet your appetite, presented as yearbook superlatives: 594